These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24595521)

  • 1. Economic evaluation of using a genetic test to direct breast cancer chemoprevention in white women with a previous breast biopsy.
    Green LE; Dinh TA; Hinds DA; Walser BL; Allman R
    Appl Health Econ Health Policy; 2014 Apr; 12(2):203-17. PubMed ID: 24595521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.
    Freedman AN; Graubard BI; Rao SR; McCaskill-Stevens W; Ballard-Barbash R; Gail MH
    J Natl Cancer Inst; 2003 Apr; 95(7):526-32. PubMed ID: 12671020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost effectiveness of tamoxifen in the prevention of breast cancer.
    Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
    Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
    Imai H; Kuroi K; Ohsumi S; Ono M; Shimozuma K
    Breast Cancer; 2007; 14(1):81-7. PubMed ID: 17245000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen for breast cancer prevention: a framework for clinical decisions.
    Cykert S; Phifer N; Hansen C
    Obstet Gynecol; 2004 Sep; 104(3):433-42. PubMed ID: 15339751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
    Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
    Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
    Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis.
    Ozanne EM; Esserman LJ
    Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2043-52. PubMed ID: 15598759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The benefits and costs of tamoxifen for breast cancer prevention.
    Eckermann SD; Martin AJ; Stockler MR; Simes RJ
    Aust N Z J Public Health; 2003; 27(1):34-40. PubMed ID: 14705265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
    Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
    Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
    Rocchi A; Verma S
    Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the effect of tamoxifen chemoprevention on long-term mortality in white women at high risk of breast cancer.
    Maucort-Boulch D; Roy P
    Eur J Cancer Prev; 2006 Aug; 15(4):347-52. PubMed ID: 16835505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis.
    Hershman D; Sundararajan V; Jacobson JS; Heitjan DF; Neugut AI; Grann VR
    J Clin Oncol; 2002 Jan; 20(1):9-16. PubMed ID: 11773148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
    Hall PS; McCabe C; Stein RC; Cameron D
    J Natl Cancer Inst; 2012 Jan; 104(1):56-66. PubMed ID: 22138097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
    Skedgel C; Rayson D; Dewar R; Younis T
    Breast Cancer Res Treat; 2007 Mar; 101(3):325-33. PubMed ID: 16897433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision analysis of tamoxifen for the prevention of invasive breast cancer.
    Grann VR; Sundararajan V; Jacobson JS; Whang W; Heitjan DF; Antman KH; Neugut AI
    Cancer J; 2000; 6(3):169-78. PubMed ID: 10882333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
    Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.